AI-Designed TB treatment could be safer and more effective than standard care
NCT ID NCT07467252
First seen Apr 14, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This study tests whether a two-drug combination (pyrazinamide and hydroxychloroquine) chosen by artificial intelligence works better than the usual four-drug regimen for adults with new, drug-sensitive lung tuberculosis. About 200 participants will receive either the AI-optimized pills or standard care for 6 months, with 6 more months of follow-up. The goal is to see if the new approach clears the infection faster and causes fewer liver side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Riyadh First Health Cluster, Ministry of Health
Riyadh, Riyadh Region, 11176, Saudi Arabia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.